Skip to content
value.today

Sage Therapeutics, Inc.

Total raised
$48 M
2 rounds on record
Latest round
$38 M
Mar 2014
First round on record
Jan 2014
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Sage Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$650 MAmount not plausible as filed$250 million to $1 billion

Sage Therapeutics, Inc.: Private sale, Dec 2020

Investors in this round

1 investor had bought by the notice of Jan 15, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sage Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$650 M of $650 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert J. Robichaud · Executive Officer
  • Anne Marie Cook · Executive Officer
  • Barry Greene · Executive Officer, Director
  • Jeffrey M. Jonas · Executive Officer, Director
  • Kimi Iguchi · Executive Officer
  • Michael Cloonan · Executive Officer
  • Stephen J. Kanes · Executive Officer
  • Elizabeth F. Barrett · Director
  • Geno F. Germano · Director
  • George F. Golumbeski · Director
  • James F. Frates · Director
  • Kevin P. Starr · Director
  • Michael F. Cola · Director
  • Steven F. Paul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jennifer Fitzpatrick, Vice President, Corporate Counsel. Source: SEC Form D, newest notice filed Jan 15, 2021. Read the notice at the SEC.

equitySEC
Mar 2014$38 MNo. 2$10 to $50 million

Sage Therapeutics, Inc.: Raise no. 2, Mar 2014

Investors in this round

15 investors had bought by the notice of Mar 24, 2014: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sage Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffery M. Jonas · Executive Officer, Director
  • Kimi M. Iguchi · Executive Officer
  • Kevin T. Starr · Director
  • Robert T. Nelsen · Director
  • Steven T. Paul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kimi Iguchi, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 24, 2014. Read the notice at the SEC.

equitySEC
Jan 2014$10 MNo. 1$10 to $50 million

Sage Therapeutics, Inc.: Raise no. 1, Jan 2014

Investors in this round

3 investors had bought by the notice of Jan 21, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sage Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffery M. Jonas · Executive Officer, Director
  • Kimi M. Iguchi · Executive Officer
  • Kevin T. Starr · Director
  • Robert T. Nelsen · Director
  • Steven T. Paul · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by /s/Kimi Iguchi, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 21, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sage Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jan 2021

That is all the official record says: Sage Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Sage Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Arch Venture Fund VII LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ARCH Venture Partners VII, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ARCH Venture Partners VII, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Third Rock Ventures GP II, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Third Rock Ventures II, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TRV GP II, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sage Therapeutics, Inc.
NameRoleNamed in
Albert J. RobichaudExecutive officerJan 2021
Anne Marie CookExecutive officerJan 2021
Barry GreeneExecutive officerJan 2021
Jeffrey M. JonasExecutive officerJan 2021
Kimi IguchiExecutive officerJan 2021
Michael CloonanExecutive officerJan 2021
Stephen J. KanesExecutive officerJan 2021
Jeffery M. JonasExecutive officerMar 2014
Kimi M. IguchiExecutive officerMar 2014
Barry GreeneDirectorJan 2021
Elizabeth F. BarrettDirectorJan 2021
Geno F. GermanoDirectorJan 2021
George F. GolumbeskiDirectorJan 2021
James F. FratesDirectorJan 2021
Jeffrey M. JonasDirectorJan 2021
Kevin P. StarrDirectorJan 2021
Michael F. ColaDirectorJan 2021
Steven F. PaulDirectorJan 2021
Jeffery M. JonasDirectorMar 2014
Kevin T. StarrDirectorMar 2014
Robert T. NelsenDirectorMar 2014
Steven T. PaulDirectorMar 2014